Testosterone/Sildenafil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Testosterone/Sildenafil Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Testosterone/Sildenafil can convert its Small molecule drug profile and AR x PDE5A biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Testosterone/Sildenafil (query alias: Testosterone/Sildenafil) |
|---|---|
| Modality / target | Small molecule drug; AR x PDE5A; AR agonists, PDE5A inhibitors |
| Highest global status | Phase 2 |
| Originator | EB Beheer Almere BV |
| Active developers | EB Beheer Almere BV |
The MCP disease footprint includes Sexual Dysfunctions, Psychological. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| TCTR20260718003 | Phase 1/2 | Recruiting | 40 | Primary endpoint not disclosed in English source |
| CTR20262012 | Not Applicable | Recruiting | 12 | Primary endpoint not disclosed in English source |
| NCT07568574 | Not Applicable | Enrolling by invitation | 60 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Testosterone therapy effects adipose distribution in older females post hip-fracture: The STEP-HI study
Phase 2; n=66; evaluation: Positive. Reported fields: %AAT = 0.52 % ; %AAT = 0.42 %
Transdermal testosterone gel vs placebo in women with diminished ovarian reserve prior to in vitro fertilization: a randomized, clinical trial
Phase 3; n=288; evaluation: Negative. Reported fields: Clinical pregnancy rate = 15.7 % ; Clinical pregnancy rate = 14.9 %
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
Phase 4; n=92; evaluation: Not stated in English source. Reported fields: Change (%) from baseline in stiffness of radius at 6 months(Mean) = 1.2 % change ; Change (%) from baseline in stiffness of radius at 6 months(Mean) = 1.6 % change
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Testosterone/Sildenafil addresses Sexual Dysfunctions, Psychological. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 14 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-08-13 | Androlabs appoints EffRx as commercial partner for Testavan® in Switzerland | Approved | Financial terms not disclosed |
| 2023-04-25 | Advanz Pharma to globally acquire Kyowa Kirin's Tostran for the treatment of male hypogonadism. | Approved | Financial terms not disclosed |
| 2022-01-10 | Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto Rico | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Drug delivery system”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical combination, process and kit thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
